Skip to main content
Premium Trial:

Request an Annual Quote

BD's Q2 Revenues Drop Slightly While Biosciences Biz Rises 3 Percent

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues were down less than 1 percent year over year, but its BD Biosciences segment managed three percent revenue growth for the quarter.

The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.74 billion for the three-month period ended March 31, down from revenues of $1.75 billion in the second quarter of 2008.

Its Biosciences business segment had revenues of $303.8 million for the quarter, up 3 percent from revenues of $294.1 million for Q2 2008. The segment's revenues include a .7 percent positive impact from currency translation.

The BD Medical segment had revenues of $897.3 million for the quarter, down around 3 percent from $922.3 million, and including a nearly 5 percent negative impact from currency translation. The BD Diagnostics segment had revenues of 539.6 million, up 1.7 percent from revenues of $530.6 million for the second quarter of 2008, and including a negative foreign currency impact of around 3 percent.

BD's net income for Q2 was $261.3 million, or $1.06 per share, down from $276.2 million, or $1.09 per share, for Q2 2008.

Its R&D expenses increased roughly 3 percent to $98.7 million from $96 million, while its SG&A spending rose 6 percent to $440.5 million from $415.5 million.

BD did not report its cash position as of the end of the second quarter.

The firm expects to report EPS growth of between 7 percent and 9 percent for full-year 2009.

Filed under

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.